Omixon announce today that Holotype HLA™ and other Omixon products will be featured in six poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) on Kos, in Greece. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the EFI accreditation process for NGS using the latest EFI standards and feature three presentations from current Holotype HLA users in Europe.
Among the posters presented by Omixon’s customers, Amalia Dinou from the Hellenic Cord Blood Bank in Athens performed a comparison between two different configurations of Holotype HLA genotyping a total of 1115 loci in their study. Only four loci were not successfully genotyped, and 100% accuracy at the 2nd field was observed among the 1111 loci that were successfully genotyped (P108). Additionally, Dr. Milena Ivanova from the Bulgarian Bone Marrow Donor Registry in Sofia will present a poster on the comparison between Illumina TruSight HLA and Omixon’s Holotype HLA in which she demonstrates a lower hands on time for Holotype HLA and superior genotyping accuracy in the results due mostly to lower rates of ambiguity (P109).
Rounding out the scientific content, Omixon will present two posters. Head of Lab and Field Operations, Efi Melista will present “Holotype HLA Early Access Program Results: An “Uncontrolled” Study” which will focus on the performance of Holotype in the hands of 24 labs across 13 countries that have genotyped more than 2500 samples. Among the participating labs were the Danish Bone Marrow Donor Registry, Brugge-Oostende Hospital, Geneva University Hospital, Paris Saint-Louis Hospital, Royal Liverpool and Broadgreen University Hospital and Torino Piemonte BMDR, Italy. Market Development Manager, Nora Nagy will present “The Economics of NGS: A Cost Comparison of NGS implementations with legacy technologies”, with a focus on educating the HLA community on the financial benefits of NGS, not just the scientific benefits. Chief Commercial Officer at Omixon Dr. Peter Meintjes notes that “The EFI meeting will once again play host to some of the most significant advancements in the adoption of NGS in clinical routine. Omixon is delighted to have featured strongly in the milestones achieved as the HLA community continues to migrate to NGS” Omixon at EFI 2016 May 11-14. | Omixon will be exhibiting at Booth #103 throughout the conference May 11, 9.30 am-10:30pm | Introduction to NGS-based HLA Typing (Basic Workshop) May 12, 1:30pm-2:30pm | EFI 2016 Symposium – NGS Accreditation with EFI Standards Omixon featured in posters P87 | E. Melista et al. (2016) – Holotype HLA Early Access Program Results: An “Uncontrolled” Study P105 | S. Vermeire et al. (2016) – Comparison of 2 reagent kits and 3 software applications for NGS-based HLA genotyping P106 | C. L. Malmberg et al. (2016) – Evaluation of National Marrow Donor Program Quality Control samples by Long Range Sequencing by multiple NGS platforms and kits. P108 | A. Dinou et al. (2016) – Validation and implementation of NGS HLA Typing: The HCBB experience. P109 | M. Ivanova et al. (2016) – Evaluation of NGS approach for HLA Typing. P110 | M. Christiansen et al. (2016) – Important factors to achieve correct results. P116 | V. Van Sandt et al. (2016) – Next or third gen? What do we need in a clinical setting? A comparison of the most prevalent and newest workflows available using the same sample test. P117 | N. Nagy. et al. (2016) – The Economics of NGS: A Cost Comparison of NGS implementations with legacy technologies
May 11, 11am-noon | Resolving Complex Cases of NGS-based HLA Typing (Advanced Workshop)
